Marsh & McLennan (MRSH)
Servicios financieros / Corretaje de seguros y consultoría
Marsh is the world's largest insurance and reinsurance broker, with a complementary consulting business (Mercer, Oliver Wyman, NERA Economic Consulting); it generates recurring commission and fee income with very low invested capital, a regulatory and scale moat, and today trades at a reported-earnings multiple above the range the insurance-broker archetype justifies according to Fairly valued, with an estimated 5-year return of +9%.
- Price
- $194.52
- Intrinsic value (5y, base)
- $262
- Total annual return (5y)
- 8.6%
- Status (nominal)
- Fairly valued
- Margin of safety
- +17%
The essentials
- Global leader as stated in the company's own 10-K: "the world's largest insurance broker and risk advisor," present in 130 countries with more than 95,000 colleagues.
- Capital-light model: TTM capex is only about 1.1% of revenue; growth is financed almost entirely with operating cash, with no material operating leverage.
- Recent reported growth (FY2025 +10.3%, TTM +8.3%) is inflated by the McGriff acquisition (Nov-2024, US$7.75bn); underlying organic growth runs around 4-5% per year.
- Returns nearly all free cash flow to shareholders via a growing dividend and share buybacks (~2% annual reduction in share count).
Intrinsic value — two valuation methods
Total return at 5 years: 8.5%/year = 6.1% appreciation + 2.4% dividend. The target price ($262) is ex-dividend; the $27 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $240 · Multiples $233) exceeds the market price ($195).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $195 trades ~16.7% below its value discounted to today (~$233); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($262) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$148.
Thesis
The business
Global leader in insurance brokerage and consulting, capital-light, with recurring revenue based on commissions and fees, a scale and regulatory moat, and a disciplined complementary M&A strategy. Business quality is high under the three pillars of Quality Investing: strong cash generation, high return on capital, and an attractive reinvestment runway via complementary acquisitions.
The valuation
Valued by P/E on comparable net income, insurance-broker archetype (16-22x band). The base case uses an exit multiple of 19x on net income projected 5 years out, with growth decelerating from the current organic level (~5%) toward a terminal ~4.5%. The resulting 5-year value implies Fairly valued with an annual return of +9%.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The market price today implies a TTM P/E of ~23.7x, above the top of the archetype band (22x), reflecting TTM earnings depressed by the Greensill litigation charge (US$425M) and the recognized quality of the business. The margin of safety depends on earnings normalizing and the multiple converging toward the 16-22x range.
What to watch
The central disconfirmer is whether organic growth (currently 4-5%) holds up without the boost from large M&A like McGriff, and whether a "soft" insurance market (falling premium rates) compresses Marsh Risk's commission base more than modeled. Also watch the final resolution of the Greensill litigation and the pace of execution of the Thrive program (targeted annualized savings of US$400 million starting in 2028).
Educational / informational. Does not constitute investment advice.